Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) shot up 3.7% during mid-day trading on Monday . The company traded as high as $135.14 and last traded at $133.42, with a volume of 1,974,691 shares. The stock had previously closed at $128.60.

A number of brokerages recently issued reports on ALXN. Oppenheimer Holdings Inc. reissued an “outperform” rating and set a $228.00 price target on shares of Alexion Pharmaceuticals in a research note on Tuesday, April 26th. Vetr raised Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $170.00 price target for the company in a research note on Monday, April 25th. BMO Capital Markets started coverage on Alexion Pharmaceuticals in a research note on Wednesday, April 6th. They set a “market perform” rating and a $165.00 price target for the company. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $212.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, June 6th. Finally, Credit Suisse Group AG reaffirmed a “hold” rating and set a $186.00 target price (down from $195.00) on shares of Alexion Pharmaceuticals in a research report on Monday, June 6th. Seven equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $186.61.

The stock’s 50-day moving average is $124.20 and its 200 day moving average is $139.41. The company has a market capitalization of $29.96 billion and a price-to-earnings ratio of 335.70.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.17 by $0.04. The firm earned $753 million during the quarter, compared to analyst estimates of $743.18 million. During the same quarter in the prior year, the firm posted $1.44 EPS. The company’s quarterly revenue was up 18.4% on a year-over-year basis. Equities analysts expect that Alexion Pharmaceuticals Inc. will post $4.71 earnings per share for the current year.

In related news, EVP John B. Moriarty sold 918 shares of the stock in a transaction on Monday, June 13th. The stock was sold at an average price of $135.72, for a total value of $124,590.96. Following the transaction, the executive vice president now owns 51,360 shares of the company’s stock, valued at $6,970,579.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Martin Mackay sold 4,097 shares of the stock in a transaction on Monday, May 16th. The shares were sold at an average price of $139.20, for a total value of $570,302.40. Following the completion of the transaction, the executive vice president now directly owns 42,706 shares in the company, valued at approximately $5,944,675.20. The disclosure for this sale can be found here.

A number of institutional investors have bought and sold shares of the stock. KBC Group raised its position in Alexion Pharmaceuticals by 46.7% in the third quarter. KBC Group now owns 22,138 shares of the biopharmaceutical company’s stock valued at $3,462,000 after buying an additional 7,045 shares during the period. Robeco Institutional Asset Management B.V. raised its position in Alexion Pharmaceuticals by 18.9% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 9,909 shares of the biopharmaceutical company’s stock valued at $1,890,000 after buying an additional 1,574 shares during the period. Principal Financial Group Inc. raised its position in Alexion Pharmaceuticals by 2.3% in the fourth quarter. Principal Financial Group Inc. now owns 316,710 shares of the biopharmaceutical company’s stock valued at $60,412,000 after buying an additional 7,145 shares during the period. Aberdeen Asset Management PLC UK raised its position in Alexion Pharmaceuticals by 17.8% in the fourth quarter. Aberdeen Asset Management PLC UK now owns 61,840 shares of the biopharmaceutical company’s stock valued at $10,313,000 after buying an additional 9,357 shares during the period. Finally, Advantus Capital Management Inc raised its position in Alexion Pharmaceuticals by 2.7% in the fourth quarter. Advantus Capital Management Inc now owns 21,882 shares of the biopharmaceutical company’s stock valued at $4,174,000 after buying an additional 583 shares during the period.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.